Schedule your call

Case Study: Manufacturing Strategy & Quality Oversight Program for a Clinical-Stage Biotech Using CDMOs

Dominic Lindner

12.03.2026

Case Study

Case Study Overview

For clinical-stage biotechs moving toward Phase III, defining a manufacturing strategy and building effective CDMO Quality Oversight are critical. Without structured governance, outsourced operations can cause delays, compliance gaps, and investor concerns. This case study shows how GMP Bridge supported a biotech with facilities in North America and Europe by delivering a risk-based manufacturing strategy and implementing a robust Quality Oversight framework.

The Challenge

A fast-growing clinical biotech preparing for Phase III needed to define its manufacturing approach while scaling operations. With multiple CDMOs, no formal oversight model, and increasing delays in batch release, the company required strategic guidance and hands-on implementation to regain control over outsourced manufacturing.

Solution Delivered

GMP Bridge supported the organization in designing a robust manufacturing and oversight strategy to enable scalable production while maintaining full regulatory compliance. The engagement focused on strategic sourcing decisions, CDMO oversight, and the establishment of a sustainable governance framework.

Make-or-Buy Strategy Analysis

Conducted a comprehensive make-or-buy analysis to guide strategic decisions between in-house manufacturing and outsourced production.

CDMO Quality & Compliance Evaluation

Assessed potential CDMO partners from a Quality and compliance risk perspective to ensure alignment with regulatory expectations.

Manufacturing Strategy Definition

Defined the optimal manufacturing setup to support late-phase development and future commercial production goals.

Quality Oversight Framework Design

Established a formal Quality Oversight framework and governance model to manage CDMO relationships effectively.

Performance Monitoring & KPI Implementation

Introduced structured KPIs to monitor CDMO performance, strengthen transparency, and drive operational accountability.

Operational Oversight Implementation

Implemented structured oversight routines covering batch release, deviation management, and change control processes.

Impact and Results

The engagement delivered a scalable manufacturing strategy and a structured oversight model, enabling stronger control over outsourced production while improving operational efficiency and regulatory confidence.

Clear Manufacturing Strategy

A risk-based manufacturing strategy was established, aligning development timelines with long-term commercialization and supply chain requirements.

Faster Batch Release and Deviation Resolution

Improved oversight processes reduced batch release delays and enabled faster deviation assessment and resolution.

Robust Quality Oversight Program

A formal Quality Oversight framework strengthened governance and ensured tighter control over CDMO manufacturing activities.

Stronger CDMO Collaboration

Structured governance and performance monitoring improved accountability and collaboration between internal teams and CDMO partners.

Increased Investor and Regulatory Confidence

The strengthened supply chain governance framework enhanced confidence in manufacturing reliability from both investors and regulatory stakeholders.

Want to see how we can deliver results like this for your site?

Schedule your Call

Company Details

  • Region: North America & Europe
  • Company: Clinical-stage biotech preparing for Phase III
  • Products: Recombinant proteins and sterile drug product (vials)

Ready to talk the specifics?
So Are we - Get in Touch

  • (+49) 174 957 5861
  • contact@gmpbridge.com

Last Case Studies